Based on the compelling in vitro and in vivo findings, the next logical step was to explore whether the attenuation of ischemia-induced platelet activation and oxylipin biosynthesis by CDNF could potentially mitigate ischemic brain damage following dMCAo. The gene discussed is CDNF; the disease is ischemia.